Abstract. The present study aimed to investigate the efficacy of a myeloid dendritic cell (mDCs) and plasmacytoid (p)DC combined vaccine loaded with heat-treated cancer cell lysates against lung cancer cells. The mDCs and pDCs were selected using magnetic bead sorting. Antigen loading was performed by adding heat-treated Lewis lung cancer cell lysates to mDC, pDC or mDC+pDC (1:1). Surface expression of CD80, CD86, CD40 and major histocompatibility complex (MHC)-II molecules were determined using flow cytometry, and the secretion of cytokines IL-12, IL-6 and TNF-α were assessed using ELISA assays. The effect of the mDC and pDC vaccine on cytotoxic T lymphocytes (CTLs) against tumor cells was investigated. Tumor-bearing nude mice were intravenously injected with the mDC and pDC combined vaccine. Tumor tissues were collected for hematoxylin and eosin and TUNEL staining. Loading with tumor cell lysate significantly upregulated the surface expression of costimulatory molecules MHC-II on DCs and enhanced secretions of IL-6, IL-12 and TNF-α by DCs. In addition, the tumor cell lysate-loaded mDC and pDC combined vaccine significantly promoted lymphocyte proliferation and enhanced CTL-mediated cytotoxicity against Lewis lung cancer cells compared with mDC or pDC treatment alone. Furthermore, intravenous injection of the mDC and pDC combined vaccine into tumor-bearing nude mice significantly inhibited subcutaneous tumor growth and induced necrosis and apoptosis within the tumor tissue. Overall, the pDC and mDC combination vaccine loaded with heat-treated Lewis lung cancer cell lysate had a synergistic effect on the induction of T lymphocyte proliferation and antitumor efficacy, which may be associated with the upregulation of co-stimulatory molecules and cytokine secretions.

Introduction

Lung cancer is the leading cause of cancer-associated mortality worldwide (1). Despite advances in surgery, chemotherapy, radiotherapy and molecular targeted therapy, the prognosis of lung cancer remains poor, with a 5-year survival rate ranging from 4-17% (2). Therefore, there is a need to develop new therapeutic strategies for the treatment of lung carcinoma.

Dendritic cells (DCs) are the most potent antigen-presenting cells with a critical role in both the primary and secondary immune response against tumor-associated antigens (TAAs) (3). Vaccinations using DCs loaded with tumor lysates or specific tumor-associated peptides can trigger cytotoxic T cell responses against TAAs (4). However, the antitumor activity of DC vaccines remains unsatisfactory in animal models and clinical trials (5). DCs comprise of heterogeneous cell populations, the two main populations being plasmacytoid (p)DCs and myeloid (m)DCs (6). mDCs and pDCs are functionally distinct, with different toll-like receptors (TLRs; pDCs express TLR7 and TLR 9, whereas mDC express all TLRs except TLR7 and TLR9) (7) and cytokines secretion (for example, mDCs secret INF-λ, while pDCs secrete INF-α) following stimulation (8,9). It has been shown that mDCs and pDCs can act synergistically, resulting in improved antitumor efficacy of the vaccine. For example, a mouse model showed that a pDCs and mDCs combined vaccine has a synergistic effect and results in improved antigen-specific antitumor efficacy against thymoma compared with a pDC or mDC alone vaccine (10). However, the antitumor efficacy of a pDC and mDC combined vaccine against lung cancer remains to be investigated.
Antigens loading serves an important role in the antitumor efficacy of DCs vaccines (4). Antigens used for vaccination include peptides, DNA and recombinant tumor proteins, tumor lysates, heat shock proteins, whole tumor cells and whole tumor RNAs (11,12). A vaccine containing a single TAA is limited and elicits tumor-associated major histocompatibility complex (MHC) class I responses but not MHC class II and CD4+ T cell helper responses (13). Meanwhile, tumor lysate or whole tumor cells contain a full complement of TAAs, including both MHC class I and class II-restricted epitopes, thus decreasing the risk of immune escape (11,12). Compared with a single TAA, loading with tumor lysates in DCs induces a stronger and more extensive immunological response against tumors (14-16).

The purpose of the present study was to evaluate the therapeutic efficacy of the mDC and pDC combined vaccine loaded with lung cancer cell lysates for the treatment of lung cancer.

Materials and methods

Materials and reagents. Mouse Lewis lung cancer cells were purchased from the American Type Culture collection (https://www.lcstards-atcc.org/products/all/CRL-1642.aspx?geo_country=nl). Mouse anti-CD11b magnetic beads and mouse anti-mPDCA magnetic beads were purchased from Miltenyi Biotec GmbH. Mouse IL-6 (cat. no. 555240), IL-12 (cat. no. 555256) and TNF-α (cat. no. 555268) ELISA kits were purchased from BD Bioscience. The TUNEL assay kit was purchased from Roche Diagnostics. Unmethylated CpG oligonucleotide (CpG ODN 1826) and the lactate dehydrogenase (LDH) cytotoxicity assay kit were purchased from Sangon Biotech Co., Ltd. The Cell Counting Kit (CCK)-8 was purchased from Dojindo Molecular Technologies, Inc. Recombinant Fms-like tyrosine kinase 3 receptor ligand (rmFlt3-Ligand), CD11c-PE mAb, anti-CD11b-APC mAb, anti-B220-FITC mAb, anti-MHC-II FITC mAb, anti-CD40 PE mAb, anti-CD80 PE mAb and anti-CD86 PE mAb were all purchased from eBioscience; Thermo Fisher Scientific, Inc.

Animals. In total, 35 C57BL/6 male mice (6-8 weeks old, weighing 20-25 g) and 12 NU/Nu male nude mice (3-4 weeks old, weighing 9-11 g) were purchased from the Laboratory animal center of Sun Yat-sen University (http://zssom.sysu.edu.cn/cm/cmc/). All animals were housed under standardized conditions with a 12-h light/dark cycle, humidity (50-60%) and temperature (20-27°C) with free access to food and water. All animals were monitored daily for signs of obvious behavioral changes and physical stress, and would be euthanized if found in distress. No animals were found dead or were euthanized during the experiments. All protocols used in the present study were approved by The Institutional Animal Care and Use Committee of the Third Affiliated Hospital, Sun Yat-sen University (Guangzhou, China; approval no. 00155986). The experiment was conducted between September 2016 and March 2017.

Preparation of mDCs and pDCs. After 3-5 days of breeding, the mice were sacrificed by cervical dislocation, bone marrow cells of the femur and tibia of C57BL/6 mice were collected and lysed using red blood cell lysis buffer (Sigma-Aldrich; Merck KGaA) to obtain bone marrow mononuclear cells. The cells were resuspended with RPMI-1640 complete medium (2 mM glutamine, 50 µM 2-ME, 7 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, rmFlt3-L 100 ng/ml and 10% FBS) (Invitrogen; Thermo Fisher Scientific, Inc.) and seeded onto 6-well plates (2x10^5/ml, 1 ml/well) at 37°C in a 5% CO2 incubator.

On day 4 of culture, half of the medium was replaced, and fresh rmFlt3-L was added into the medium. On day 8, the mDC and pDC were sorted using mouse anti-CD11b and mouse anti-mPDCA magnetic beads according to manufacturer's protocol, and the cell purity was >99% according to flow cytometry analysis with a FACScaliber™ cytometer (BD Biosciences) using fluorescently-labeled monoclonal antibodies (anti-CD11c-PE mAb (cat. no. 12-0401-81), anti-CD11b-APC mAb (cat. no. 17-0201-81), anti-B220-FITC mAb (cat. no. 11-0452-81)). The analysis software used was FlowJo version 7.6.1 (FlowJo LLC). An equal amount of pDC and mDC (1:1 ratio) was used for the combination vaccine (10).

The sorted DC subsets were divided into three groups for subsequent experiments: mDCs, pDCs And mDCs: pDC (1:1). The number of the total cells was equal in the three groups.

DCs loaded with heat-treated with Lewis lung cancer cell lysates. Lewis lung cancer cells were cultured in high-sugar DMEM medium containing 100 U/ml penicillin, 100 µg/ml streptomycin and 10% FBS at a concentration of 1.5-3x10^5 cell/ml in a 37°C and 5% CO2 incubator. Lewis lung cancer cells in the logarithmic growth phase were placed in an incubator at 42°C for 1 h, followed by placing in an incubator at 37°C, 5% CO2 for 2 h. The cells were digested with trypsin, washed twice with PBS and then resuspended in PBS (1x10^5 cells/ml). The cells were repeatedly frozen and thawed in liquid nitrogen and 37°C water bath five times and centrifuged at 13,000 x g at 4°C for 10 min. The resulting supernatant was collected as cell lysates.

Equal amounts of heat-treated tumor cell lysates were added to the mDC (1x10^5), pDC (1x10^5) and mDC: pDC (1:1; 1x10^5) groups. The amount of antigen was based on the number of tumor cells before freeze-thaw treatment with DCs: Tumor cells = 1:1. The control group consisted of an equal amount of RPMI-1640 complete medium, and then CpG ODN 1826 was added to each group at a final concentration of 2 µg/ml. The cell was cultured for 24 h to induce DC maturation for subsequent experiments.

Mixed lymphocyte proliferation assay. C57BL/6 mouse spleens were taken and cut with ophthalmology scissors, placed on a 70-µm filter screen, and ground with a 1-ml syringe plunger and rinsed with PBS while grinding. The spleen cells suspension was collected in a centrifuge tube and centrifuged at 300 x g for 5 min, and the supernatant was discarded. The red blood cell lysis buffer was added and incubated for 1 min, and the RPMI-1640 medium was immediately added to stop the reaction, then centrifuged at 300 x g for 5 min. After washing twice with PBS, the resulting pellet was collected as spleen cells. These experiments were performed at room temperature ~25°C.
DCs loaded with heat-treated tumor cell lysates from the three groups of mDC, pDC and mDC+pDC were added to 96-well culture plates at 1x10^4 cells/well. C57BL/6-derived spleen cells were added into each well (1x10^6 cells/well; DCs: Spleen cells =1:10) and cultured for 3 days. The DCs of each group without tumor cell lysate loading were used as control groups. There were three duplicated wells in each group. The proliferation of spleen cells was detected using the CCK-8 assay according to the manufacturer’s protocol.

**Establishment of tumor-bearing nude mice model.** Lewis lung cancer cells in the logarithmic growth phase were used as target cells, and CTL cells were used as effector cells. The effector and target cells were mixed at the effector: target cell ratios (E:T) of 40:1 (CTL:tumor cells, 4x10^5:1x10^6), 20:1 (CTL:tumor cells, 2x10^5:1x10^6) and 10:1 (CTL:tumor cells, 1x10^5:1x10^6) in 100 µl medium, and plated onto a 96-well flat-bottom plate and co-cultured for 12 h. There were three duplicated wells in each group. At 1 h before the end of co-culture, 10 µl of LDH releasing agent (Beyotime Institute of Biotechnology) was added into each well and incubated at 37°C, 5% CO₂. After culture for a week, the cells were trypsinized and collected as the CTL cells.

Lewis lung cancer cells in the logarithmic growth phase were used as target cells, and CTL cells were used as effector cells. The effector and target cells were mixed at the effector: target cell ratios (E:T) of 40:1 (CTL:tumor cells, 4x10^5:1x10^6), 20:1 (CTL:tumor cells, 2x10^5:1x10^6) and 10:1 (CTL:tumor cells, 1x10^5:1x10^6) in 100 µl medium, and plated onto a 96-well flat-bottom plate and co-cultured for 12 h. There were three duplicated wells in each group. At 1 h before the end of co-culture, 10 µl of LDH releasing agent (Beyotime Institute of Biotechnology) was added into each well and incubated at 37°C, 5% CO₂ for 1 h. At the end of the culture, the absorbance at 490 nm (OD value) was measured using a microplate reader.

**Determination of surface markers on DCs and cytokines secretion.** For surface marker labeling, the cell suspension was incubated with anti-CD11c-PE mAb (cat. no. 12-0401-81), anti-CD11b-APC mAb (cat. no. 17-0012-81), anti-B220-FITC mAb (cat. no. 11-0452-81), anti-mouse CD80 PE-Cy7 (cat. no. 15-0801-81), anti-mouse CD86 APC (cat. no. 17-0862-81), anti-mouse CD40 PE (cat. no. 12-0401-81) and anti-mouse MHC Class II FITC (cat. no. 11-5322-81) fluorescent antibodies at 20˚C for 20 min. The cells in the wells were washed twice with PBS, resuspended in 300 µl PBS containing 1% FBS (Invitrogen; Thermo Fisher Scientific, Inc.), and subjected to flow cytometry as aforementioned. The experiment was repeated three times. The analysis software used was Flowjo version 7.6.1 (FlowJo, LLC). CD11c positive cells were gated, CD11b-B220+ was identified as pDC subpopulation and CD11b+B220- defined as mDC subpopulation. The secretion level of IL-6, IL-12 and TNF-α in the aforementioned cell supernatant was detected using the corresponding ELISA kit according to the manufacturer’s protocols.

**Preparation of CTLs.** The tumor cell lysate-sensitized mDCs and pDCs were added to the 6-well plate culture well (1x10^6/ml per well). The ratio of DCs: Antigen was 1:1, and the amount of antigen was based on the number of tumor cells before freeze-thaw treatment. DC maturation was induced by the addition of CpG ODN1826 at a final concentration of 2 µg/ml overnight. The cells in the wells were collected, and the cell suspension was prepared at the cell density of 3x10^6/ml. Mouse spleen cells were collected as aforementioned.

The DCs and spleen cells were mixed at a ratio of 1:10 and then added to a 6-well plate (3x10^5 cells/ml, 2 ml per well with 6x10^6 cells/well). rmIL-2 was added at a final concentration of 20 U/ml. The culture medium was replaced with complete RPMI-1640 medium containing IL-2 once every 3 days and then incubated for 2 weeks in a 37°C in a 5% CO₂ incubator. The resulting cells were CTLs.

**In vivo antitumor study of DC vaccine.** Tumor-bearing mice were randomly divided into three groups: Control, mDC group and the mDC+pDC group. At day 7 post the inoculation of Lewis lung cancer cells, PBS, mDC-induced CTL cells and mDC+pDC induced CTL cells (1x10^7 cells/mouse) were intravenously injected into mice in the three groups through the tail vein. The injection of CTL cells was repeated 7 days after the first injection.

The length (L) and width (D) of the tumor were measured with a vernier caliper, and the tumor volume was calculated every 2 days. The tumor volume was calculated according to the formula V=1/2LxD².

At 25 days after the inoculation of Lewis lung cancer cells, nude mice were sacrificed by cervical dislocation, and then tumor tissues were collected. The necrosis of tumor tissues was observed by hematoxylin and eosin (H&E) staining. For H&E staining, tissue samples were fixed with 10% formalin for 24 h, then embedded in paraffin and sectioned into slices with a thickness of 5 µm. After dewaxing with xylene and rehydration with descending ethanol series [100 (twice), 90, 80 and 70% respectively], the slice was stained with H for 5 min, 5% acetic acid for 1 min, and eosin staining for 1 min at room temperature ~25°C. After dehydration with ascending ethanol series (70, 80, 90 and 100% respectively), the slice was dehydrated with neutral resin, covered with a cover glass, and then mounted. TUNEL staining was used to observe the apoptosis of tumor cells by using the aforementioned TUNEL assay kit according to the manufacturer’s protocol. The apoptotic cells were observed under a fluorescence microscope (excitation light wavelength, 450-500 nm; detection wavelength, 515-565 nm).

**Statistical analysis.** All data was presented as mean ± SD and were compared using one-way ANOVA (for one independent variable) or two-way ANOVA (for two independent variables) with Sidak's post hoc test for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS version 16 software (SPSS Inc.).
Results

Combining tumor cell lysate-loaded mDC and pDC promotes lymphocyte proliferation. The effect of mDC and pDC vaccines on lymphocyte proliferation was determined using a CCK-8 assay. As shown in Fig. 1, in both the absence or presence of tumor cell lysates, the lymphocyte proliferation was significantly higher in the mDC+pDC group compared with the mDC or pDC group (all $P<0.05$). After loading with tumor cell lysate, the promotive effect on lymphocytes proliferation was significantly increased in the three groups (all $P<0.001$ without tumor lysate vs. with tumor lysate; Fig. 1).

Combining tumor cell lysate-loaded mDC and pDC enhances CTL-mediated cytotoxicity against tumor cells. The effect of mDC and pDC vaccines on CTL cytotoxicity against tumor cells was investigated. In the absence of tumor cell lysates, there was no difference in CTL cytotoxicity among the three groups at all the effector:target ratios (E:T), (all $P>0.05$; Fig. 2).

Tumor cell lysate loading significantly enhanced the CTL-mediated cytotoxicity in all the groups at all the E:T (all $P<0.001$ without tumor lysate vs. with tumor lysate; Fig. 2). At all the three E:T, the mDC+pDC group had significantly higher cytotoxicity compared with the mDC or pDC group (all $P<0.05$; Fig. 2). The cytotoxicity of the mDC+pDC group was 31.68, 54.77 and 73.01% at the E:T of 1:10, 1:20 and 1:40 (Fig. 2), respectively.

Heat-treated tumor cell lysate loading upregulates the DCs surface expression of costimulatory molecules. Surface expressions of costimulatory molecules, including CD80, CD86, CD40 and MHC-II, were assessed using flow cytometry (Fig. 3A). The results showed that in the absence of tumor cell lysate, the surface expressions of MHC-II were significantly higher in the mDC+pDC/TCL$^+$ group compared with the mDC/TCL$^-$ or pDC/TCL$^+$ group (all $P<0.05$; Fig. 3B). After loading with the tumor cell lysate, the surface expressions of CD86 and MHC-II were significantly higher in the mDC+pDC/TCL$^+$ group compared with those in the mDC/TCL$^-$ or pDC group/TCL$^+$ (all $P<0.05$; Fig. 3B). In addition, after loading with the tumor cell lysate, surface expression of MHC-II was significantly increased in all cell types (all $P<0.05$; Fig. 3B).

Tumor cell lysate loading stimulates cytokines secretion in DCs. The secretion of cytokines in DCs was determined using ELISA kits. As shown in Fig. 4, tumor cell lysate loading significantly upregulated the secretions of IL-6, IL-12 and TNF-$
 \alpha$ in the mDC+pDC=1:1 group (all $P<0.001$). In addition, in both the absence or presence of tumor cell lysates, secretions of IL-6, IL-12 and TNF-$
 \alpha$ were significantly higher in the mDC+pDC group compared with those in the mDC or pDC group (P<0.05; Fig. 4), except for mDC:pDC without tumor lysate vs. mDC without tumor lysate for IL-6.

mDC and pDC combined vaccine inhibits tumor growth in nude mice. The in vitro results indicated that DCs vaccines loaded with tumor cell lysates induced a strong antitumor effect, and the mDC and pDC combined vaccine loaded with tumor cell lysates exhibited a synergistic antitumor effect in vivo. To further evaluate the antitumor effect of the mDC and pDC combined vaccine in vivo, a tumor-bearing nude mice model was established. The pDC alone group was not included in the animal study because this group exhibited the lowest in vitro antitumor effect. After 7 days post subcutaneous inoculation of Lewis lung cancer cells in nude mice, all mice developed a subcutaneous mass and were administrated with the first DC vaccine. At 14 days after inoculation, a second DC vaccine was administrated. It was observed that between 11 and 25 days after inoculation, the tumor volume was significantly lower in the mDC+pDC group compared with the control group (all $P<0.05$ or $P<0.01$; Fig. 5B). In addition, the tumor volume was all significantly lower in the mDC+pDC group compared with the mDC group (Fig. 5B). This result suggested that the mDC and pDC combined vaccine had a good in vivo antitumor effect.

Histological changes of tumor cells after mDC and pDC combined vaccine treatment. Histological changes in tumor cells following DC vaccine treatment were evaluated. H&E staining showed that in the control group, the tumor cells had different sizes and obvious atypia (Fig. 6A, black arrow). The cancer cells were round, elliptical or fusiform in shape. There was no tumor giant cell or necrosis. Tumor cells in the mDC group exhibited massive necrosis and hemorrhage (Fig. 6B, blue arrow), while those in the mDC+pDC group exhibited massive necrosis and hemorrhage (Fig. 6C, white arrow).

mDC and pDC combined vaccine treatment induces apoptosis in tumor cells. A TUNEL assay was performed to assess the number of apoptotic tumor cells after DC vaccine treatment (Fig. 7A-C). The results showed that the number of apoptotic tumor cells was significantly higher in the mDC+pDC=1:1 group compared with the mDC group and the control group (both P<0.01; Fig. 7D), indicating that the mDC and pDC combined vaccine treatment decreased apoptosis within the tumor.
Figure 2. DCs cells induce cytotoxic T lymphocytes cytotoxicity against lung cancer cells. Two-way ANOVA with Sidak’s post hoc test. **P<0.001 vs. the same cell type without tumor lysate treatment. *P<0.05 vs. mDC group. $P<0.05$ vs. pDC group with the same treatment. m, myeloid; p, plasmacytoid; DCs, dendritic cells.

Figure 3. Surface expression of costimulatory molecules. (A) Flow cytometry results and (B) quantification. Data were analyzed using a two-way ANOVA with Sidak’s post hoc test. *P<0.05 vs. the same cell type without tumor lysate treatment. $P<0.05$ vs. mDC group. $P<0.05$ vs. pDC group with the same treatment (with or without tumor lysate). m, myeloid; p, plasmacytoid; DCs, dendritic cells; TCL-, without heat-treated tumor cell lysate; TCL+, loaded with heat-treated tumor cell lysate.
The use of the DC vaccine for tumor immunotherapy has not yet achieved satisfactory results (5). Therefore, how to enhance the antigen presentation ability of the DC vaccine in vivo and how to improve the clinical efficacy of the vaccine have been focuses of research. The present study evaluated the therapeutic efficacy of the mDC and pDC combined vaccine loaded with heat-treated cancer cell lysates for the treatment of lung cancer and the underlying mechanism. The results showed that tumor cell lysate loading upregulated surface expression of costimulatory molecules on DCs and enhanced secretions of IL-6, IL-12 and TNF-α in the mDC+pDC=1:1 group. In addition, combining tumor cell lysate-loaded mDCs and pDCs significantly promoted lymphocyte proliferation and enhanced CTL-mediated cytotoxicity against Lewis lung cancer cells compared with mDC or pDC alone treatment. Furthermore, intravenous injection of the mDC and pDC combined vaccine into tumor-bearing nude mice significantly inhibited subcutaneous tumor growth and induced necrosis and apoptosis within the tumor tissue. Taken together, these results suggested that the combined pDC and mDC vaccine loaded with heat-treated Lewis lung cancer cell lysate had a synergistic effect on the induction of T lymphocyte proliferation and antitumor efficacy. This synergistic antitumor effect may be associated with the upregulation of co-stimulatory molecules and cytokine secretions.

The method for preparing tumor lysates affects the efficacy of the DCs vaccine. It has been shown that freeze-thaw tumor cell lysates do not effectively mimic in vivo immunogenic necrosis and inhibit the maturation and function of DCs (17-20). Hatfield et al (20) reported that heat-treated tumor lysates (≥42˚C) compared with tumor lysates are more effective TAAs for DC vaccination. DCs loaded with heat-treated tumor cell lysates can induce strong and broad T cell responses against pancreatic cancer, thereby enhancing antitumor effects (21). Heat treatment increases the synthesis of heat shock protein (HSP) in tumor cells, and HSP may promote the expression of TAAs and enhance their presentation to antigen-presenting cells (22). Stress-induced HSP can also induce the expression of MHC-II molecules, and cytokine and chemokine secretions in DCs (23). Therefore, the present study adopted heat treatment to prepare tumor cells lysates for DC vaccination.
The present study used nude mice to generate a tumor model. In our preliminary study, C57BL rats were used to generate a tumor model, but the rate of tumor formation was low, with a small tumor volume and relatively long tumor growth time. However, the nude mice used in this study resulted in a significantly higher rate of tumor formation, with larger tumor volumes and shorter tumor growth times.

Figure 6. Hematoxylin and eosin staining of tumor tissue of (A) the control, (B) mDC and (C) mDC+ plasmacytoid DC groups. Black arrow indicates the tumor cells with obvious atypia. Blue arrow indicates focal necrosis and hemorrhage, while arrow indicates massive necrosis and hemorrhage. Magnification, x200. m, myeloid; DCs, dendritic cells.

Figure 7. TUNEL staining of tumor tissue of the (A) control (A), (B) mDC (B) and (C) mDC+pDC groups. Magnification, x200. Three fields were observed for each group. (D) The number of tumor cell apoptosis in the mDC: pDC=1:1 group was significantly higher than that in the mDC and Control groups. One-way ANOVA with Sidak's post hoc test. **P<0.01 vs. the mDC+pDC group. m, myeloid; p, plasmacytoid; DCs, dendritic cells.
formation time (unpublished data). In addition, DC-activated lymphocytes, rather than the DC vaccine, were transplanted into the animals. The C57BL rats inoculated with subcutaneous tumor would produce specific T cells against tumor that can affect the antitumor activity of the injected DC-activated lymphocytes. Since nude mice lack lymphocytes, this problem can be overcome. In the present study, the experimental animals were the NU/NU nude mice that lack thymus and T lymphocytes (24). The activation of T lymphocytes requires antigen and accessory molecules to effectively induce CTL formation (25). Therefore, the DC vaccines could not be directly injected into tumor-bearing nude mice. T lymphocytes should be activated in vitro and then the CTL effector cells infused into the animal. Previous studies have shown that antigen-loaded DCs induce T lymphocytes in vitro, and infusion of CTL effector cells exhibits significant antitumor effects in mice (26-28), which are in line with the present results.

Liu et al (10) demonstrated that pDCs and mDCs have a synergistic effect on the induction of antigen-specific antitumor immune responses. Piccioli et al reported that human mDC and pDC mixed culture can upregulate the expression of DC activation markers CD40, CD80 and CD83, which can enhance the proliferation of allogeneic T cells and secrete more IFN-γ compared with single pDC or mDC alone (29). Consistent with these observations, the present results demonstrated that compared with mDC or pDC alone treatment, combining tumor lysate-loaded mDC and pDC enhanced lymphocyte proliferation and CTL-mediated cytotoxicity in vitro. The in vitro experiments showed that the mDC and pDC combined vaccine inhibited subcutaneous tumor growth, and induced extensive necrosis, hemorrhage and apoptosis within the tumor tissue. The efficacy of the combined vaccines was improved compared with that of the mDC group. These results suggested that the mDC and pDC combined vaccine exhibited a synergistic antitumor effect against lung cancer cells. To the best of our knowledge, the present study is the first to demonstrate the efficacy of mDC and pDC vaccine combined against lung cancer. To the best of our knowledge, the present study is the first to demonstrate the efficacy of mDC and pDC vaccine combined against lung cancer. Moreover, to minimize the number of animals used, the pDC alone group was not included in the animal study because this group exhibited the lowest in vitro antitumor effect. All these limitations should be addressed in the future study.

In summary, the present study suggested that the mixed culture of mDC and pDC produced a synergistic effect, which enhanced the cytotoxic effect of T lymphocytes against Lewis lung cancer cells in vitro and in vivo. These results may help improve the design and clinical efficacy of DC vaccines.

Acknowledgements

Not applicable.

Funding

The study was supported by The Science and Technology Planning Project of Guangdong Province (grant no. 20130319c).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

LG and JZ designed the study. HC and JT conducted the experiments, collected and analyzed the data and drafted the manuscript. XL guided and performed the experiments and revised the manuscript. HL, WW and YW cultured the cells and determined the level of cytokines. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

All protocols used in the present study were approved by The Institutional Animal Care and Use Committee of the Third Affiliated Hospital (Guanzhou, China; approval no. 00155986).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Mellstedt H, Vansteenkiste J and Thatcher N: Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. Lung Cancer 73: 11-17, 2011.
2. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Mellstedt H, Vansteenkiste J and Thatcher N: Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. Lung Cancer 73: 11-17, 2011.
3. Gardner A and Ruffell B: Dendritic cells and cancer immunity. Trends Immunol 37: 855-865, 2016.
4. González FE, Gleiser A, Falcón-Beas F, Osorio F, López MN and Salazar-Onfray F: Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccines Immunother 10: 3261-3269, 2014.

5. Ilett E, Prestwich R and Melcher A: The evolving role of dendritic cells in cancer therapy. Expert Opin Biol Ther 10: 369-379, 2010.

6. Bol KF, Schreiber G, Gerritsen WR, De Vries IJM and Figdor CG: Dendritic cell-based immunotherapy: State of the art and beyond. Clin Cancer Res 22: 1897-1906, 2016.

7. Kadowaki N, Ho S, Antonenko S, Maley C, Kastelein R, Bazan F and Liu Y: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194: 863-869, 2001.

8. Swiecki M and Colonna M: The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 15: 471-485, 2015.

9. Nizzoli G, Krietsch J, Weick A, Steinfeldt S, Facciotti F, Gruiarin P, Bianco A, Stekel B, Moro M, Crosti M, et al: Human CD1c+ dendritic cells secrete high levels of IL-12 and potentially prime cytotoxic T-cell responses. Blood 122: 932-942, 2013.

10. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P and Wang G: Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 178: 1534-1541, 2007.

11. Mocellin S, Mandruzzato S, Bronte V, Lise M and Nitti D: Part I: Vaccines for solid tumours. Lancet Oncol 5: 681-689, 2004.

12. Schuler G, Schuler-Thurner B and Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15: 138-147, 2003.

13. Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM and Buonaguro L: Antigen-specific vaccines for cancer treatment. Hum Vaccines Immunother 10: 3332-3346, 2014.

14. Ridolfi R, Petroni M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M, Migliori G and Riccobono A: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 4: 36, 2006.

15. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, Sparber K, Sterry W and Walden P: Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: Immunological effects and clinical results. Vaccine 23: 2367-2373, 2005.

16. Nagayama H, Satoh K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakamura T, et al: Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13: 521-530, 2003.

17. Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrell ML, DeSilva C and Lett M: Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53: 125-134, 2004.

18. Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF and Puisieux I: Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother 55: 254-267, 2006.

19. Zhang Y, Yoneyama H, Wang Y, Ishikawa S, Hashimoto S, Gao JL, Murphy P and Matsushima K: Mobilization of dendritic cell precursors into the circulation by administration of MIP-1alpha in mice. J Natl Cancer Inst 96: 201-209, 2004.